Know Cancer

or
forgot password

A Phase 1, Open-label, Dose-escalation Study Of The Safety And Pharmacokinetics Of SNX-5422 Mesylate In Subjects With Refractory Solid Tumor Malignancies Or Non-Hodgkin's Lymphoma


Phase 1
18 Years
N/A
Not Enrolling
Both
Cancer

Thank you

Trial Information

A Phase 1, Open-label, Dose-escalation Study Of The Safety And Pharmacokinetics Of SNX-5422 Mesylate In Subjects With Refractory Solid Tumor Malignancies Or Non-Hodgkin's Lymphoma


Inclusion Criteria:



- >18 years old

- histologically confirmed solid tumor malignancy

- refractory to available therapy or for which no therapy is available

- adequate organ function

Exclusion Criteria:

- CNS malignancy

- significant GI disease

- at risk for prolonged QT interval

Type of Study:

Interventional

Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

adverse events and other safety assessments

Outcome Time Frame:

continuous

Safety Issue:

Yes

Principal Investigator

Pfizer CT.gov Call Center

Investigator Role:

Study Director

Investigator Affiliation:

Pfizer

Authority:

United States: Food and Drug Administration

Study ID:

B1311001

NCT ID:

NCT00506805

Start Date:

June 2007

Completion Date:

March 2010

Related Keywords:

  • Cancer
  • solid tumor malignancy; Hsp90
  • Neoplasms
  • Lymphoma, Non-Hodgkin

Name

Location

Pfizer Investigational SiteFlagstaff, Arizona  86001
Pfizer Investigational SiteBristol, Tennessee  37620